From UPMC: For More Info, Go Here…
ngd- Another example of “Killing us softly” with price hikes….
Over the course of a decade, out-of-pocket costs for multiple sclerosis drugs rose more than sevenfold for Medicare Part D beneficiaries, according to a JAMA Neurology
study published today by researchers at the University of Pittsburgh
Using Medicare claims data from 2006-2016, the researchers looked at trends in multiple sclerosis
drug prices over time. Not only did they find steep increases in list prices — the starting point before rebates, coupons or insurance kicks in — but also in the ultimate costs to both Medicare and its recipients.
“We wanted to see how increases in list prices translated to increases in out-of-pocket spending, and we discovered that actual price increases do get passed down to patients, and that can negatively affect access,” said study senior author Inmaculada Hernandez, Pharm.D., Ph.D.
, assistant professor of pharmacy at Pitt.
Several drugs on the market reduce the frequency and severity of multiple sclerosis flare-ups, which can involve a variety of disabling neurological symptoms, such as vision loss, pain, fatigue and muscle weakness.
From 2006-2016, the annual list prices of these drugs more than quadrupled, ballooning from about $18,000 to nearly $76,000 per patient per year.